Rinvoq ER 30 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FAWAZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,352
Award facts
- Contract value 100% obligated
- $28,352.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, received a firm fixed-price delivery order valued at $28.4 million from the Defense Logistics Agency (DLA) on August 15, 2025. The award covers the supply of RINVOQ ER 30 mg tablets in quantities of 30 units, with delivery scheduled to conclude by August 18, 2025. This delivery order was issued without a set-aside designation and represents performance at the company's location in Conshohocken, Pennsylvania. The award was made under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its woman-owned small business status to compete effectively in DLA procurements. The company maintains a robust portfolio of pharmaceutical product deliveries across multiple therapeutic categories, including prescription medications, biologics, and medical consumables for Department of Defense healthcare sites. This delivery order for RINVOQ ER, a pharmaceutical product supporting military health facilities, exemplifies the company's consistent role in providing specialized pharmaceutical items to support defense healthcare requirements.
Quick answers
Who was awarded contract SPE2DB25FAWAZ?
SPE2DB25FAWAZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 15, 2025.
How much is contract SPE2DB25FAWAZ worth?
The government has obligated $28,352 on SPE2DB25FAWAZ.
Is contract SPE2DB25FAWAZ an order under another contract?
Yes. SPE2DB25FAWAZ is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAWAZ competed?
The extent of competition for SPE2DB25FAWAZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award